Unlocking Brain Repair with Intranasal VHH Therapeutics
From Stroke Survival to Recovery
Vision:
We envision a future where surviving a stroke is only the beginning—and where recovery is transformed by therapies that help the brain repair itself.
Synap Biotech is developing intranasal VHH therapeutics designed to unlock neuroplasticity and restore function after stroke, with a platform that may ultimately extend to traumatic brain injury, CTE, and other neurological disorders.
Mission:
Our mission is to develop first-in-class intranasal VHH therapeutics that unlock the brain's natural capacity for repair with the goal of restoring neurological function following stroke. By targeting the biological barriers that limit recovery, we are building a platform with the potential to transform treatment for traumatic brain injury, CTE, and other neurological disorders.